Posted by Michael Wonder on 30 Apr 2018
Final NICE nod for Keytruda in bladder cancer
30 April 2018 - MSD’s Keytruda has become the only immunotherapy to be funded by the NHS for the treatment of bladder cancer, following a final green light from cost regulators.
The National Institute for Care and Health Excellence is endorsing use of the drug within the cancer drugs fund (CDF) for untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable.
The guideline stipulates that Keytruda (pembrolizumab) should be stopped at two years of uninterrupted treatment or earlier in the event of disease progression.
